635318-55-7

635318-55-7 structure

Name: Pomaglumetad Methionil
Chemical Name: (1R,4S,5S,6S)-4-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-2,2-dioxo-2λ6-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid
CAS Number: 635318-55-7
Molecular Formula: C₁₂H₁₈N₂O₇S₂
Molecular Weight: 235.214
Catalog: Signaling Pathways GPCR/G Protein mGluR
Create Date: 2017-07-05 11:38:07
Modify Date: 2024-01-17 21:58:34
LY2140023 is an orally active prodrug of LY404039. LY404039 is a selective metabotropic glutamate 2/3 receptor agonist. LY2140023 is currently for the treatment of schizophrenia[1].

Name	(1R,4S,5S,6S)-4-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-2,2-dioxo-2λ6-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid
Synonyms	UNII-3V85EZ3KFQ 2-Thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid, 4-amino-, 2,2-dioxide, (1R,4S,5S,6S)- LY-404,039 Pomaglumetad methionil (1R,4S,5S,6S)-4-Amino-2-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid 2,2-dioxide

Description	LY2140023 is an orally active prodrug of LY404039. LY404039 is a selective metabotropic glutamate 2/3 receptor agonist. LY2140023 is currently for the treatment of schizophrenia[1].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> mGluR Research Areas >> Neurological Disease
Target	mGluR2 mGluR3
In Vivo	LY2140023 (orally; 3, 10, and 300 mg/kg; once daily for 7 days) dose-dependent increases the levels of the dopamine metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA)[1]. Animal Model: Male Fischer rats (approximately 250 g)[1] Dosage: 3, 10, and 300 mg/kg Administration: Orally; once daily for 7 days Result: Dose-dependent increased the levels of the dopamine metabolites DOPAC and HVA.
References	[1]. Lowe S, et al. Effects of a novel mGlu_₂/₃ receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid. Psychopharmacology (Berl). 2012 Feb;219(4):959-70.